2.92
+0.015(+0.52%)
Currency In USD
| Previous Close | 2.9 |
| Open | 2.91 |
| Day High | 3.01 |
| Day Low | 2.8 |
| 52-Week High | 5.17 |
| 52-Week Low | 0.86 |
| Volume | 740,963 |
| Average Volume | 2.42M |
| Market Cap | 208.22M |
| PE | -5.61 |
| EPS | -0.52 |
| Moving Average 50 Days | 2.74 |
| Moving Average 200 Days | 1.58 |
| Change | 0.02 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $265 as of December 26, 2024 at a share price of $2.915. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $1,567.2 as of December 26, 2024 at a share price of $2.915.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 03, 2024 9:30 PM GMT
WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today anno
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 9:30 PM GMT
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Ac
Aclaris Therapeutics Announces $80 Million Private Placement
GlobeNewswire Inc.
Nov 18, 2024 1:10 PM GMT
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today ann